H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Evotec (EVO) to $7 from $8 and keeps a Buy rating on the shares following the Q2 report. The firm says softness in biotech funding could continue to hurt the company’s revenue in the near-term.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVO:
- Evotec AG Reports Mixed H1 2025 Performance
- Evotec AG: Buy Rating Backed by JEB Growth and Strategic Asset Sale
- Evotec AG Reports H1 2025 Results and Strategic Developments
- Evotec SE Announces Potential Sale of Toulouse Biologics Site to Sandoz
- Sandoz to acquire Just-Evotec Biologics from Evotec for $300M